TABLE 1

Summary of patient demographics

Males/femalesAge yearsFEV1 LFEV1 %predFVC LFEV1/FVC ratioSmoking history pack-yearsLung cancer lesionRecorded medications
SABLABICS
COPD, current smoker10/670.9 (60–82)1.9 (0.9–3.5)74.6 (53–96)3.3 (1.7–5.4)59.0 (46–75)56.9 (9–124)Yes744
COPD, ex-smoker17/272.1 (60–80)1.7 (1.3–2.5)64.8 (45–118)3.0 (2.4–4.5)56.3 (42.5–69.3)48.7 (11–112)Yes9129
No airflow obstruction, current smoker4/1364.4 (44–78)2.3 (1.6–3.3)105.2 (70–131)3.1 (2.1–4.4)73.1 (66.9–82.5)44.2 (15–90)Yes000
No airflow obstruction, ex-smoker9/872.1 (57–84)2.1 (1.2–3.2)91.9 (47–127)2.9 (1.8–4.1)71.2 (55–85.8)37.3 (2.1–117)Yes111
Never smoker0/368.3 (65–71)1.9 (1.8–2.0)108.3 (100–113)2.7 (2.2–3.6)82.5 (77–91)0 (0)Yes101
Average for lung cancer group40/32 (total)69.8 (44–84)2.0 (0.87–3.5)84.8 (45–131)3.1 (1.69–5.4)65.5 (42.5–90.9)44.1 (0–124)Yes181715
Healthy, never smoker controls7/352.2 (31–75)3.3 (2.3–4.18)107 (82.7–148.6)4.3 (2.9–5.6)78.6 (70.8–95.1)0.0 (0)No000

Subject demographics of cancer patients (n=72) and healthy nonsmoker control subjects (n=10). Data are presented as the mean (range) or n. FEV1: forced expired volume in 1 s; FVC: forced vital capacity; SAB: short-acting bronchodilators; LAB: long-acting bronchodilators; ICS: inhaled corticosteroid.